| Tolerability of aminosalicylates in inflammatory bowel disease. | |
| | |
MedLine Citation:
|
PMID: 11437696 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Since its synthesis in the 1930s and subsequent introduction, sulfasalazine has been an effective treatment for inflammatory bowel disease. However, up to one-third of patients are unable to take the drug because of severe intolerance. The finding in 1977 that the anticolitic effect of sulfasalazine lay in its 5-aminosalicylic [(5-ASA); mesalazine] moiety led to the development of new generations of 5-ASA agents. These new agents include a slow continuous release formulation, pH-dependent release formulations, formulations using alternative carrier molecules and rectally administered formulations. Newer 5-ASA formulations are more effective than placebo in maintaining remission of ulcerative colitis. They have also been used for the treatment of active Crohn's disease as well as maintenance treatment of ileocolonic Crohn's disease, although their role in isolated small bowel disease is controversial. In general terms, all of the newer 5-ASA preparations are much better tolerated than sulfasalazine. The use of standard dosages of mesalazine in pregnancy appears to be tolerated; however, continuing surveillance of pregnancy outcome is recommended. While there is evidence that mesalazine can cause nephrotoxic reactions, these reactions can occur with all 5-ASA-containing preparations, particularly in individuals with existing renal disease. Blood dyscrasias can also occur with all aminosalicylates. |
| | |
Authors:
|
S Ishaq; J R Green |
Related Documents
:
|
7795286 - Clinical course of inflammatory bowel disease during treatment with interferon for asso... 2493426 - Nutritional management of inflammatory bowel disease. 2304046 - Chlamydia trachomatis and inflammatory bowel disease--a coincidence? 3595356 - Spleen size in patients with inflammatory bowel disease. does it have any clinical sign... 16870296 - Internalization of jembrana disease virus tat: possible pathway and implication. 20941906 - New data on aetiology of nodular gill disease in rainbow trout, oncorhynchus mykiss. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy Volume: 15 ISSN: 1173-8804 ISO Abbreviation: BioDrugs Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-07-04 Completed Date: 2001-08-16 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9705305 Medline TA: BioDrugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 339-49 Citation Subset: IM |
Affiliation:
|
Queen Elizabeth Hospital, Birmingham, England. sauidshaq@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aminosalicylic Acids
/
adverse effects*,
therapeutic use Humans Inflammatory Bowel Diseases / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Aminosalicylic Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Immunological aspects of alzheimer's disease: therapeutic implications.
Next Document: Serum leptin levels in pregnant women with type 1 diabetes mellitus.